<DOC>
	<DOCNO>NCT01077401</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability , bioactivity , dose response two different dosage ( 0.5 mg 2.0 mg ) ranibizumab ( RBZ ) patient diabetic macular edema ( DME ) .</brief_summary>
	<brief_title>Ranibizumab Edema Macula Diabetes : Protocol 3 With High Dose - READ 3 Study</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Signed informed consent authorization use disclosure protect health information Age ≥18 year Diagnosis diabetes mellitus ( type 1 type 2 ) Serum HbA1c ≥ 5.5 % within 12 month randomization . Retinal thicken secondary diabetes mellitus ( diabetic macular edema ) involve center fovea Diagnosis must confirm fluorescein angiography OCT image Foveal thickness ≥ 250 μm , Best correct visual acuity score study eye 20/40 20/320 inclusive ( Snellen equivalent use ETDRS protocol distance 4 meter ) . The nonstudy eye must ≥ 20 letter ( approximate Snellen equivalent 20/400 ) . In opinion investigator , decrease vision study eye due foveal thicken DME obvious cause decrease vision If female childbearing potential , negative pregnancy test commitment use least two form effective contraception ( birth control ) duration study necessary . Panretinal photocoagulation macular photocoagulation within 3 month study entry study eye Use intraocular periocular injection steroid study eye ( e.g. , triamcinolone ) within 3 month study entry Previous participation study receipt antiangiogenic drug ( pegaptanib sodium , ranibizumab , bevacizumab , anecortave acetate , protein kinase C inhibitor , etc . ) within 2 month study entry Proliferative diabetic retinopathy study eye , exception Inactive , fibrotic proliferative diabetic retinopathy regress follow panretinal laser photocoagulation OR Tufts NVE le one disc area vitreous hemorrhage Vitreomacular traction epiretinal membrane study eye evident biomicroscopically OCT Structural damage center macula study eye likely preclude improvement visual acuity follow resolution macular edema , include atrophy retinal pigment epithelium , subretinal fibrosis , laser scar ( ) , macular ischemia , organize hard exudate plaque Ocular disorder study eye may confound interpretation study result , include retinal vascular occlusion , retinal detachment , macular hole , choroidal neovascularization cause ( e.g. , AMD , ocular histoplasmosis , pathologic myopia ) Concurrent disease study eye could compromise visual acuity require medical surgical intervention first 6month study period Cataract surgery study eye within 3 month study entry ; YttriumAluminum Garnet ( YAG ) laser capsulotomy within 1 month study entry ; intraocular surgery within 3 month precede Day 0 . History vitreoretinal surgery study eye within 3 month study entry Uncontrolled glaucoma ( defined intraocular pressure ≥30 mm Hg despite treatment antiglaucoma medication ) Blood pressure exceed 180/100 ( sit ) screen period Uncontrolled diabetes mellitus , evidence glycosylated hemoglobin ( HbA1c ) value &gt; 13 % Renal failure require dialysis renal transplant Premenopausal woman unwilling commit adequate contraception History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug , might affect interpretation result study , render subject high risk treatment complication INR ≥ 3.0 ( e.g . due current treatment warfarin ) . The use aspirin anticoagulant exclusion History cerebral vascular accident , myocardial infarction , transient ischemic attack within 3 month study enrollment . Have history hypersensitivity ranibizumab component Have presence active malignancy , include lymphoproliferative disorder . Subjects history fully resolve basal squamous cell skin cancer may enrol . Other Inability comply study followup procedure Any condition investigator believe would pose significant hazard subject investigational therapy initiate . Participation another simultaneous medical investigation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Diabetic</keyword>
	<keyword>edema</keyword>
	<keyword>DME</keyword>
</DOC>